TABLE 3

Overall Characteristics of 82 ER+/HER2– BC Patients Without Distant Metastases at Baseline Staging

CharacteristicNo. of patients (%)Mean
Histologic type*
 Invasive ductal, no special type74 (90%)
 Lobular6 (7%)
 Other2 (3%)
Grade*
 Grade 15 (6%)
 Grade 256 (68%)
 Grade 321 (26%)
Progesterone expression*
 Negative27 (33%)
 Positive55 (67%)
Pathologic response rate†
 pCR4 (5%)
 Non pCR78 (95%)
18F-FDG PET/CT tumor characteristic
 SUVmax
  PET1 tumor SUVmax7.0 (range, 1.8–19.2)
  PET2 tumor SUVmax4.4 (range, 1–16.9)
  ΔSUVmax−36% (range, −93% to +7%)
 TLG
  PET1 tumor TLG94.8 (range, 3.6–3,168.0)
  PET2 tumor TLG55.5 (range, 1.1–2,007.0)
  ΔTLG−40.7% (range, −98.1% to +101.6%)
Patient follow-up
 Follow-up time (median)35 (range, 10–71)
 No recurrence71 (87%)
 Recurrence11 (13%)
 Deceased1 (1%)

  • ↵* Tumor histology and immunohistochemistry determined on biopsy before NAC.

  • ↵† Pathologic findings determined on surgical tissues after NAC.